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Fig. 2. X-ray film of the right hand shows marked soft 
tissue calcification and subperiosteal resorption of the 
phalanges. 
over the same period. l-6 Certain patient characteristics 
have been found to correlate with development of aortic 
stenosis over a short period of time including increased age, 
low physical work capacity at the time of presentation,l and 
a low gradient on the initial study.3p 4 Other studies, how- 
ever, have failed to identify any risk factors that predict 
rapid progression of calcific aortic valve stenosis.5, 6 
In adults under the age of 60 years, aortic stenosis occurs 
most commonly in the setting of congenital abnormalities 
or following rheumatic fever or endocarditis.7 Humoral 
factors such as hypercalcemia may also play an important 
role in valvular calcification and stenosis but have gained 
little attention in the literature. This patient lacked any 
known predisposing valvular abnormalities yet experi- 
enced extensive calcification involving both the aortic valve 
leaflets and mitral valve annulus over the same period that 
her calcium and phosphate levels were increased. The con- 
comitant severe metastatic calcification of her soft tissues 
suggests that secondary hyperparathyroidism was the ma- 
jor causative factor in the subacute development of severe 
aortic stenosis. 
Multiorgan soft tissue calcification commonly occurs in 
patients with chronic renal failure and has been shown to 
affect the heart in at least one third of dialysis patients.8 
Although several mechanisms may be involved, secondary 
hyperparathyroidism is thought to be a major causative 
factor. In a postmortem study, parathyroid hyperplasia 
was found in all six patients with chronic renal failure, who 
were shown to have extensive calcification of the conduc- 
tion system.g This is the first report, to our knowledge, of 
the rapid development of aortic stenosis from metastatic 
calcification of a morphologically normal valve. 
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Provocation of ventricular tachycardia by 
an automatic implantable cardioverter 
defibrillator 
William H. Kou, MD, Marvin M. Kirsh, MD, Mack C. 
Stirling, MD, Alan H. Kadish, MD, Carl E. Orringer, 
MD, and Fred Morady, MD. Ann Arbor, Mich. 
The automatic implantable cardioverter defibrillator 
(AICD) has been used to treat patients with life-threat- 
ening ventricular arrhythmias, and its efficacy in prevent- 
ing sudden death has been demonstrated.lm3 Several possi- 
ble complications have been recognized as being associated 
with implantation of the AICD; however, there have been 
no previous reports of a malignant arrhythmia being 
induced by an AICD. We describe herein a patient who re- 
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Fig. 1. Nonsustained VT provoked by an AICD shock. The shock was triggered by sinus tachycardia, rate 
152 beats/min; there was no VT preceding the AICD shock. 
Fig. 2. Sustained VT, 250 beats/min, provoked by an AICD shock. The shock was triggered by sinus 
tachycardia. 158 beats/min. The VT was terminated by a subsequent AICD shock approximately 12 sec- 
onds later. 
ceived multiple AICD discharges during sinus tachycardia 
and in whom each AICD discharge provoked ventricular 
tachycardia (VT). 
A 66-year-old man was admitted for treatment of sus- 
tained VT. He had a history of myocardial infarction 32 
years earlier and had experienced episodes of sustained VT 
for 5 years. On several occasions, direct-current counter- 
shocks were required to terminate episodes of VT. Cardiac 
catheterization revealed high-grade stenoses in the left 
main coronary artery, the left anterior descending artery, 
the left circumflex artery and the right coronary artery. The 
left ventricular ejection fraction was 31% . The patient un- 
derwent triple-vessel coronary artery bypass graft surgery. 
Because of his history of VT, epicardial AICD patches and 
rate-sensing leads were implanted at the time of bypass 
surgery for later use with an AICD. Postoperative electro- 
physiologic testing demonstrated inducible, sustained, 
monomorphic VT, which had a cycle length of 240 msec. 
The VT was refractory to quinidine. An AICD pulse gen- 
erator was then implanted. The pulse generator was a 
Ventak model 1520 AICD (Cardiac Pacemaker, Inc., St. 
Paul, Minn.), which had a rate detection cutoff of 152 
beats/min and no probability density function criterion. 
Testing at the time of implantation of the pulse generator 
demonstrated that sustained, monomorphic VT was suc- 
cessfully terminated by the first AICD discharge. 
After discharge from the hospital, the patient partici- 
pated in an exercise rehabilitation program. The heart 
rhythm was monitored during exercise, and the first two 
sessions of the rehabilitation program were uneventful, 
with the maximum heart rate during exercise remaining 
under 150 beats/min. However, during the third session in 
the recovery phase of a Stairmaster exercise program, the 
patient experienced three AICD discharges. Each of the 
shocks was triggered by sinus tachycardia at rates of 152 to 
158 beats/min. The first two shocks precipitated nonsus- 
tained VT, 9 to 10 beats in duration (Fig. 1). The third 
shock, which was synchronized to the QRS complex, pro- 
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voked an episode of sustained VT, rate 250 beats/min, ac- 
companied by palpitations and symptoms of near-syncope 
(Fig. 2). A subsequent AICD discharge successfully re- 
stored sinus rhythm (Fig. 2). 
This case report demonstrates that AICD discharges 
may be proarrhythmic. Although proarrhythmia was never 
observed during predischarge testing, a synchronized shock 
triggered by sinus tachycardia reproducibly induced VT 
immediately after exercise. This case documents a previ- 
ously unreported complication of the AICD and empha- 
sizes the importance of selecting an appropriate rate cutoff 
to avoid the triggering of shocks by sinus or supraventric- 
ular tachycardia. Although the proarrhythmic potential of 
the AICD shocks was not apparent during predischarge 
testing, shocks were never delivered during sinus rhythm. 
It is possible that ischemia and/or sympathetic activation 
associated with exercise may have facilitated the induction 
of VT by the AICD. 
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Low levels of atrial natriuretic factor in 
patients with atrial standstill 
Takumi Sumimoto, MD, Mareomi Hamada, MD, 
Akihiro Nagae, MD, Yukio Kazatani, MD, and 
Kunio Hiwada, MD. Ehime, Japan 
Atria1 standstill is a rare arrhythmia that is caused by the 
degeneration of atria1 myocardium.’ Echocardiography 
usually reveals large atria in patients with atria1 standstill. 
Atria1 natriuretic factor (ANF) is secreted from atria1 my- 
ocytes and has potent natriuretic, diuretic, and vasodilator 
effects. Elevated plasma concentrations of ANF have been 
reported in patients with various cardiac diseases.2s 3 The 
predominant stimulus for ANF release appears to be 
increased atria1 transmural pressure with associated atria1 
stretch.4 To elucidate whether or not atrial myocardium in 
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Fig. 1. Correlation between left atria1 diameter and 
plasma concentration of atria1 natriuretic factor (ANF). 
Symbols represent the following patient groups: 0, mitral 
valve disease; 0, atria1 standstill (*1, patient No. 1; *2, pa- 
tient No. 2). 
patients with atria1 standstill can secrete ANF, we mea- 
sured plasma concentration of ANF in two patients with 
atria1 standstill, and the data were compared with those in 
10 patients with mitral valve disease. 
Patient No. 1. A go-year-old man was admitted to the 
hospital because of hypotension. He had been treated for 
congestive heart failure for the past 7 years. A grade 3/6 
holosystolic murmur was heard at the apex. Electrocardio- 
gram showed junctional rhythm and absence of P wave in 
all leads. Chest x-ray films showed a remarkable cardiac 
enlargement. Echocardiography revealed no atria1 contrac- 
tion. Atria1 standstill was suspected because of these find- 
ings, Right atrial electrogram revealed complete absence of 
atria1 activity. Atria1 activity could not be elicited with an 
electrical stimulus of 10 V. We made a diagnosis of atria1 
standstill. Mean right atria1 and right ventricular pressures 
(systolic/end-diastolic) were 21 and 50/18 mm Hg, respec- 
tively. The patient died suddenly 2 months after the initial 
measurement of plasma ANF concentration. 
Patient No. 2. A 69-year-old man was admitted to the 
hospital for the surgical correction of abdominal aortic 
aneurysm. He underwent mitral valve replacement at 64 
years of age. A grade 416 holosystolic murmur was heard at 
the apex. Electrocardiogram showed junctional rhythm 
and absence of P wave in all leads. Chest x-ray films showed 
a remarkable cardiac enlargement and pleural effusion. 
Furosemide was administered orally for the treatment of 
heart failure. After treatment, pleural effusion disap- 
peared. Atria1 contraction was not proved on echocardio- 
gram. Diagnosis of atria1 standstill was confirmed by 
electrophysiologic study. Mean right atria1 and right ven- 
tricular pressures (systolic/end-diastolic) were 20 and 88/ 
12 mm Hg, respectively. 
Mitral valve disease. We studied 10 patients with mitral 
valve disease (mean age, 50 + 5 years) as control popula- 
